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Detection of viral DNA is essential for eliciting mammalian innate immunity. However, viruses have acquired
effective mechanisms for blocking host defense. Indeed, in this issue of Cell Host & Microbe, Wu et al. (2015)
discover a herpesviral strategy for inhibiting the prominent host sensor of viral DNA, cGAS.For all metazoa, continual surveillance of
the intracellular milieu is essential for
both detecting and responding to viral in-
fections. To this end, cells utilize special-
ized receptor proteins termed ‘‘sensors’’
that recognize pathogen-derived moi-
eties, such as viral DNA, to subsequently
initiate antiviral responses. In mammals,
these events are required for mobilizing
the innate and adaptive arms of the im-
mune system and, ultimately, for path-
ogen clearance. Consequently, these
cellular mechanisms exert extreme selec-
tive pressures on viruses, driving the
evolution of unique viral gene products
that target and disable important host
defenses. Understanding virus immune
evasion strategies used to inhibit host
sensors of viral DNA can accelerate
the design of effective therapeutics that
directly hinder pathogen fitness.
In this issue,Wuet al. (2015)makeasub-
stantial leap forward in this research area
by discovering a viral strategy for inhibiting
one of the most prominent sensors of viral
DNA, cGAS (cyclic GMP-AMP synthase).
To place this study in its biological context,
recent work has demonstrated that cGAS
directly binds to foreign DNA in the cyto-
plasm, triggering a cascade of events
that culminates in the expression of anti-
viral cytokines (Figure 1, steps 1–6) (Sun
et al., 2013; Wu et al., 2013). Specifically,
cGAS catalyzes the production of cGAMP
(cyclic guanosine monophosphate–aden-
osine monophosphate) from cellular ATP
andGTPpools. In turn, thecGAMPsecond
messenger binds to the ER transmem-
brane adaptor protein STING (stimulator
of interferon genes), triggering activation
of theproteinkinaseTBK-1and IRF3 (inter-
feron regulatory factor 3) (Ablasser et al.,
2013). Subsequently, IRF3 translocates
into the nucleus where it orchestrates the270 Cell Host & Microbe 18, September 9, 20expression of immune and inflammatory
genes, such as interferons (ifn). Under-
scoring the significance of this sensor in
recognizing multiple pathogens, cGAS
was shown to be required for triggering
immune responses during infection with
several DNA viruses and bacterial patho-
gens. Interestingly, however, cGAS (also
known as C6ORF150 andMab-21 domain
containing 1, MB21D1) was initially found
as a potent inhibitor of several RNA vi-
ruses in a screen of over 380 interferon-
stimulated genes (Schoggins et al., 2011).
This suggests that cGAS may possess
additional broad-acting antiviral activities.
Along these lines, cGAS was also recently
demonstrated to interact with and stabilize
another DNA sensor, the interferon induc-
ible protein IFI16 (Orzalli et al., 2015).
Initially identified as a cytoplasmic sensor,
several groups have later demonstrated
that IFI16 also acts as a nuclear DNA
sensor, being required for STING-depen-
dent IFN expression in response to infec-
tions with the nuclear-replicating viruses
herpes simplex virus 1 (HSV-1) and human
cytomegalovirus (HCMV).
Although the discovery of DNA sensors
is a major step forward in understanding
the barriers to pathogen replication, it rep-
resents only one side of the host-path-
ogen interaction. On the opposing side
are the diverse viral immune evasion stra-
tegies, which have remained less charac-
terized. Progress has beenmade in recent
years, in which a few virus factors that
inhibit DNA sensors during herpesvirus
infections have been identified. During
HSV-1 infection, the viral E3 ubiquitin
ligase ICP0 was shown to promote the
proteasome-dependent degradation of
IFI16 (Orzalli et al., 2012) (Figure 1, step
8). In contrast, during HCMV infection,
the viral tegument protein pUL83 was15 ª2015 Elsevier Inc.shown to bind IFI16, preventing its DNA-
dependent oligomerization (Li et al.,
2013) (Figure 1, step 9). Both of these viral
strategies effectively abate IFI16- and
STING-dependent IFN expression. Sur-
prisingly, given the enormously expanded
interest in DNA sensing, no immunoeva-
sion mechanism targeting cGAS has yet
been described.
Here, Wu et al. (2015) address this
important gap in knowledge by identifying
a viral strategy for inhibiting cGAS. The
study is a true tour de force with respect
to the diversity of cellular, biochemical,
and molecular techniques employed to
reveal a virus immunoevasion mechanism
during infection with Kaposi sarcoma-
associated herpesvirus (KSHV). Specif-
ically, the authors define the poorly
characterized tegument protein ORF52
as a potent inhibitor of the central cGAS-
STING signaling axis (Figure 1, step 7).
For this, each KSHV open-reading frame
(>80) was individually assayed for its
ability to attenuate an IFN reporter driven
by cGAS activity. Of the KSHV ORFs
that reduced IFN reporter stimulation,
only ORF52 displayed both DNA-binding
activity and cytoplasmic localization.
ORF52 also inhibited the stimulation of
IRF3 in humanmonocytes upon challenge
with either DNA substrates or Vaccinia
virus, a DNA virus that replicates in the
cytoplasm. Interestingly, cells stimulated
with cGAMP still initiated immune sig-
naling independent of ORF52 expres-
sion, suggesting that ORF52 may dir-
ectly inhibit cGAS function, rather than
affecting a downstream pathway compo-
nent. To substantiate this model, the
authors demonstrated in vitro that purified
ORF52 drastically reduces cGAS pro-
duction of cGAMP in the presence of
DNA. Thus, ORF52 may function directly
Figure 1. Herpesvirus Strategies for Abating Host DNA Sensing
Fusion of the viral lipid envelope with the plasma membrane of host cells releases viral tegument
proteins and the nucleocapsid containing the virus double-stranded DNA genome (1-2). During its
transit to the nucleus, the nucleocapsid may be disrupted, releasing viral DNA into the cytosol (3).
Here cGAS binds to the viral DNA, stimulating cGAMP production from ATP and GTP (4). Subsequently,
cGAMP triggers STING to activate protein kinase TBK-1 (5), in turn activating transcription factor
IRF3. Upon dimerization, IRF3 enters the nucleus and stimulates antiviral gene expression (6). As shown
by Wu et al. (2015), during KSHV infection, the tegument protein ORF52 obstructs cGAS function
through the sequestration of viral DNA substrate and/or an interaction, which directly alters cGAS
enzymatic activity (7). In contrast, the HSV-1 E3 ubiquitin ligase ICP0 promotes degradation of the
nuclear DNA sensor IFI16 (8), whereas the HCMV tegument protein UL83 inhibits IFI16 by blocking
its oligomerization (9).
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or catalysis of cGAMP production) or
indirectly by sequestering its DNA sub-
strate. The authors provide substantial
evidence for both ORF52 functions. Using
DNA competitive binding assays, ORF52
was shown to affect the ability of cGAS
to bind its DNA substrate. Furthermore,
using an impressive mutagenesis screen,
the authors demonstrate that upon
loss of binding to DNA, ORF52 can no
longer inhibit cGAMP production in vitro.
The authors go on to establish by immu-
noaffinity purification that ORF52 and
cGAS can also interact in a DNA-inde-
pendent manner, mapping the domains
that mediate this interaction. Thus,
although ORF52 may to some extent
compete with cGAS for its DNA substrate,
it seemingly has a second mechanism
for directly targeting cGAS. Furthermore,
this inhibitory mechanism seems to be
specific for cGAS, as ORF52 expression
did not affect the functions of AIM2,another cytoplasmic DNA sensor. This
virus immune evasion mechanism was
validated in both human monocytes
and epithelial cells, as the authors show
that KSHV-induced immune responses
through the cGAS-STING signaling axis
are significantly elevated in the absence
of ORF52. Mechanism aside, the posi-
tive impact of ORF52 on KSHV fitness
is underscored by its conserved function
across the gammaherpesvirus family.
Similar to their KSHV counterpart,
ORF52 homologs from human Epstein-
Barr virus, Rhesus monkey rhadinovirus,
and Murid gammaherpesvirus 68 all
bind to both cGAS and DNA, inhibit
cGAMP production in vitro, and atten-
uate IRF3 activation upon DNA chal-
lenge. Altogether, Wu et al. (2015) pro-
vide considerable evidence that ORF52
is a critical KSHV factor targeting a
central component of the mammalian
immune system— the cGAS-STING sig-
naling axis.Cell Host & Microbe 18, SConsidering all the recent findings in
DNA sensing, this is clearly an exciting
and evolving research area. So, it is not
surprising thatmany questions still remain.
For instance, like all herpesviruses, KSHV
deposits its DNA genome into the nucleus,
where it is replicated by the viral DNA
polymerase. It is therefore challenging to
reconcile how cGAS, thought to be pre-
dominantly cytoplasmic, has the opportu-
nity to sense the viral genome. The disrup-
tion of the viral capsid within the cytosol
may explain this phenomenon, but this re-
mains to be further explored. Also, herpes-
viruses can establish a latent infection
characterized by a stably integrated, but
transcriptionally silent, viral genomewithin
certain cell types. This raises further ques-
tions about how cGAS sensing would be
affected during productive versus latent
viral infection. Additionally, cGAS has
been observed to interact with the DNA
sensor IFI16, promoting IFI16-dependent
responses to other herpesviruses. There-
fore, there are likely additional compo-
nents and crosstalk pathways that require
further characterization. Reinforcing the
immunomodulatory role of the cGAS-
STING axis, recent reports showed that
cGAMP produced in response to HIV-1
and mouse CMV infections is packaged
into progeny virions and transferred to
naive cells, stimulating their immune re-
sponses (Bridgeman et al., 2015; Gentili
et al., 2015). This may serve to rapidly
disseminate IFN signaling locally or to
slow the progress of subsequent de novo
infections. Thus, further understanding
the interaction between pathogens and
the cGAS-STING axis, as well as
continued research for new mechanisms
of viral immune evasion, is a high priority
in the race toward rational drug design.
For example, additional clarification of
the mechanism by which ORF52 specif-
ically inhibits cGAS has the promise to be
an important contributor to drug design
efforts and to expand the current under-
standing of the antagonistic interplay
between pathogens and host immunity.
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Staphylococcus aureus, like other bacterial pathogens, scavenges host iron for growth through incompletely
understood mechanisms. In this issue of Cell Host & Microbe, Spaan et al. (2015) demonstrate that two
Staphylococcus aureus leukotoxins, HlgAB and LukED, target the Duffy antigen receptor for chemokines
on erythrocytes, resulting in lysis and iron release.A bacterial pathogen entering a mamma-
lian host is placing a substantial bet on
its ability to withstand iron starvation. Mi-
crobial access to iron, which is essential
for growth, is limited by sequestration
within host cells, limited solubility of free
iron at neutral pH, and binding by host
molecules. Effective bacterial pathogens
have developed multipronged appro-
aches to liberate iron from the grip of
the host (Skaar, 2010). Such strategies
include production of small molecules
that bind free iron with exceptional affinity
(siderophores); binding and uptake of
iron-associated host factors such as lac-
toferrin, transferrin, and hemoglobin; and
liberation of iron from intracellular pools
using cytotoxins. The outcome of infec-
tion, both systemic and localized, may
hinge on the host’s ability to withstand
or to directly counteract (such as through
the production of siderophore-binding lip-
ocalins) bacterial attempts to gain access
to iron (Ganz and Nemeth, 2015).
Staphylococcus aureus is an efficient
colonizer and a particularly vexing human
pathogen that is responsible for an aston-
ishingworldwideburdenofdisease.Within
the host, S. aureus preferentially uses
hemoglobin as a source of iron (Pishchany
et al., 2014), but its specific means of
gaining access to that target have re-mained unclear. Given the diverse array
of pore-forming toxins (PFTs) produced
by S. aureus—including a-, b-, and g-he-
molysins; other bicomponent cytolysins
such as the Panton-Valentine leukocidin;
and the phenol-soluble modulins—as
well as the large reservoir of hemoglobin-
bound iron contained in circulating eryth-
rocytes, it has been hypothesized that
PFT-mediated hemolysis likely provides a
source of iron for S. aureus in vivo. How-
ever, to date, the question of which of
these PFTs target human erythrocytes
in vivo has not been resolved. A clear un-
derstanding has been confounded by the
fact that a-toxin efficiently lyses rabbit
but not human erythrocytes, and several
other S. aureus toxins are either inacti-
vatedbyserum factorsor selectively target
leukocytes rather than erythrocytes.
In this issue of Cell Host & Microbe,
Spaan et al. (2015) take a major step for-
ward in understanding the interplay
among S. aureus toxins, erythrocytes,
and pathogenesis by demonstrating that
two S. aureus bicomponent cytolysins,
HlgABandLukED,exploit theDuffyantigen
receptor for chemokines ([DARC]; also
called atypical chemokine receptor 1) as
a cellular receptor to mediate erythrocyte
lysis, thus releasing iron. DARC, a seven-
transmembrane protein expressed primar-ily on erythrocytes and endothelial cells,
has a history as an important factor in
human infectious diseases (Horuk, 2015).
As an essential receptor for invasion of
erythrocytes by Plasmodium vivax and
P. knowlesi, DARC has served as a model
to understand malaria pathogenesis and
parasite-host interactions. At the level of
human populations, there is strong evi-
dence for selection on specific DARC
allelic variants. A promoter polymorphism
that alters GATA-1 transcription factor
binding and selectively abolishes DARC
expression on erythrocytes has reached
fixation in human populations in sub-Sa-
haran Africa and is thought to be a major
factor in the absence of P. vivax disease
from that region. Other variants, including
the FY*B allele used by Spaan et al.
(2015), decrease but do not eliminate cell
surface DARC.
DARCalsoactsasapromiscuousdecoy
(non-signaling) chemokine receptor on
erythrocytes and endothelial cells. It dir-
ectly binds several chemokine ligands
and can buffer serum concentrations of
such proteins by sequestering them from
traditional, signal-transducing receptors
(Dawson et al., 2000). This ‘‘chemokine
sink’’ effect prevents rapid, high-amplitude
changes in chemokine concentrations,
alters local and systemic immunity, and
